Semaglutide storage & reconstitution.

Semaglutide (NN9535) is supplied as a lyophilised powder because the dry state is far more chemically stable than the aqueous form. The purpose of laboratory storage is to preserve the batch in the condition documented on its release Certificate of Analysis until it reaches the bench — which means protecting the vial from moisture ingress, from prolonged thermal excursion and from light.

Semaglutide's lipidated Lys26 side-chain and Aib8 substitution give the peptide its long half-life in solution but do not remove its susceptibility to slow oxidation and deamidation. The analytical view of what the release specification means lives on the Semaglutide purity page; handling detail is kept here so those pages remain focused.

Chemical degradation of Semaglutide is strongly temperature-dependent. Lower temperatures suppress the hydrolytic, oxidative and deamidation pathways that drive slow drift in NN9535 quality. A lyophilised vial held at −20 °C therefore ages far more slowly than the same vial held at ambient temperature. Short handling excursions are expected and tolerated; repeated or extended excursions are a documented cause of post-release degradation.

Always allow a frozen Semaglutide vial to equilibrate to room temperature before opening. Opening a cold vial straight into humid room air draws atmospheric moisture onto the lyophilised cake — one of the most avoidable causes of quality loss for a lipidated GLP-1 analogue.

A dedicated laboratory refrigerator at 2–8 °C with monitored temperature and controlled access is the appropriate short-term store for Semaglutide working vials and reconstituted stock. Consumer refrigerators are poorly temperature-stable — door-shelf swings of 5–10 °C on every opening are common — and are not suitable for a research peptide. Keep vials upright, away from the door, and in original packaging where possible.

Lyophilised Semaglutide tolerates long-term frozen storage well — the powder is glassy and chemically inert relative to its aqueous counterpart. Reconstituted Semaglutide is different: repeated freeze-thaw cycling stresses the peptide mechanically through ice-crystal formation and chemically through pH shifts and localised concentration effects as water freezes out. If extended storage of reconstituted material is unavoidable, aliquot at reconstitution into single-use volumes and freeze each aliquot exactly once.

Store Semaglutide vials in the dark. Ultraviolet and short-wavelength visible light drive slow oxidation of photolabile residues and should be excluded during storage. Keep vials sealed until use — lyophilised Semaglutide is hygroscopic, and moisture ingress leads to cake caking, colour change and accelerated degradation. Retain the original desiccant where supplied and discard any vial whose seal integrity is in doubt.

A well-formed Semaglutide lyophilised cake is uniform, white to off-white and occupies its expected volume in the vial. Cake collapse, meltback, discoloration or a wet appearance indicate that the batch has experienced thermal or moisture stress and should not be used without escalation. Do not tap or shake a lyophilised vial to break the cake — inspect it visually and reconstitute directly.

Reconstitution converts the lyophilised Semaglutide vial into a working solution of known concentration. The variables are three: total mass in the vial (from the label and Certificate of Analysis), diluent identity and diluent volume. Choose the diluent volume to give a working concentration that suits the downstream study — the reconstitution calculator returns the exact solvent volume for any target concentration and vial strength.

Technique matters. Draw the calculated diluent volume, add it slowly against the inner wall of the vial rather than directly onto the Semaglutide cake, and swirl gently until fully dissolved. Do not shake or vortex — mechanical stress promotes aggregation of lipidated GLP-1 analogues. Once dissolved, the Semaglutide solution should be clear and colourless.

Bacteriostatic water for injection contains 0.9% benzyl alcohol as a preservative. The preservative suppresses microbial growth in a multi-use Semaglutide vial and supports refrigerated in-use stability over several weeks. Preservative-free sterile water for injection is acceptable for same-day preparations only; any Semaglutide workflow that keeps the reconstituted vial for more than 24 hours should default to bacteriostatic water.

Store the reconstituted Semaglutide vial at 2–8 °C, upright and protected from light. As a general laboratory reference, Semaglutide reconstituted in bacteriostatic water is used within four to six weeks. Label the vial at reconstitution with the date, diluent, resulting concentration and batch number so the in-use history is fully traceable back to the released analytical record.

Any change in visual appearance — precipitate, cloudiness, colour drift — should stop use of the vial until the anomaly is resolved against the batch Certificate of Analysis.

Semaglutide storage and reconstitution sit inside the broader quality framework described on the laboratory quality page, referenced against USP General Chapters <797> and <1503>, ICH Q1A(R2) for stability testing and ICH Q5C for biological-product stability. The WHO Technical Report Series 961 Annex 9 framework informs cold-chain expectations for time- and temperature-sensitive materials.

The Semaglutide Certificate of Analysis records the batch at release. Where a batch COA reports specific stability data — recommended storage temperature, retest date, in-use limits — that batch-level record takes precedence over any general laboratory reference. The full anatomy of a COA is covered in the Certificate of Analysis guide. Confirm your vial's batch number in the verification library before opening.